Advanced Search

 

Study ID Status Title Patient Level Data
TRA100773_B Completed A double-blind, randomized, placebo-controlled, parallel group study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of SB-497115-GR, a thrombopoietin receptor agonist, administered at 30, 50 and 75 mg as oral tablets once-daily for 6 weeks to adult male and female subjects with refractory, chronic immune thrombocytopenic purpura
TRA102537 Completed A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administered for 6 months as oral tablets once daily in adult subjects with previously treated chronic ITP.
TRA103452 Completed An Open-Label, Non-Randomized Pharmacokinetic and Safety Study of a Single Oral dose of 50mg Eltrombopag in Healthy Subjects and in Volunteers with Mild, Moderate or Severe Hepatic Impairment
TRA104412 Completed An Open-Label, Non-Randomized Pharmacokinetic and Safety Study of a Single Oral Dose of 50 mg [SB-497115] in Healthy Subjects and in Subjects with Mild, Moderate, or Severe Renal Impairment
TRA106914 Completed A phase I, double-blind, placebo and observer-blind positive controlled, randomized, parallel group study in healthy subjects to investigate the photoirritant potential of eltrombopag
TRA108057 Completed An Open-label repeat dosing study of eltrombopag olamine (SB-497115-GR) in adult subjects, with chronic idiopathic thrombocytopenic purpura (ITP)
TRC105499 Completed An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen
TRX103635 Completed A randomized, double-blind, multi-center, placebo-controlled, cross-over study to determine the consistency of response for Trexima* (sumatriptan 85mg/naproxen sodium 500mg) administered during the mild pain phase for the acute treatment of multiple migraine attacks (*Treximet) Study Listed on ClinicalStudyDataRequest.com
TRX105848 Completed An Open Label, Single Dose, Parallel Group Study to Evaluate Absorption and Transit Characteristics of TREXIMA and RELPAX in Patients Inside and Outside of an Acute Migraine Attack. Study Listed on ClinicalStudyDataRequest.com
TRX105850 Completed A randomized, double-blind, single migraine attack, placebo -controlled, patallel-group multicenter study to evaluate the efficacy and tolerability or Trexima (sumatriptan succinate/naproxen sodium) tablets vs placebo when administered during the mild pain phase of menstrual migraine in women with dysmenorrhea Study Listed on ClinicalStudyDataRequest.com
TRX105852 Completed See Detailed Description Study Listed on ClinicalStudyDataRequest.com
TRX106571 Completed A Study of Combination Product (sumatriptan succinate and naproxen sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2) Study Listed on ClinicalStudyDataRequest.com
TRX106573 Completed A Study of Combination Product (sumatriptan succinate and naproxen sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) Study Listed on ClinicalStudyDataRequest.com
TRX109011 Completed A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine when administered during the Moderate-Severe Migraine Pain, 1 of 2 Study Listed on ClinicalStudyDataRequest.com
TRX109013 Completed A Crossover, Randomized, Double-blind, Double-dummy, Placebo-controlled Study to Evaluate the Efficacy of TREXIMET®/Sumatriptan + Naproxen Sodium vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine when administered during Moderate-Severe Migraine Pain, 2 of 2 Study Listed on ClinicalStudyDataRequest.com
TXA107563 Completed A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of TREXIMA* (sumatriptan succinate/naproxen sodium) for a single moderate or severe headache in adults diagnosed with probable migraine without aura (ICHD-II 1.6.1) (*TREXIMET) Study Listed on ClinicalStudyDataRequest.com
TXA107977 Completed Study TXA107977, a Long-Term Safety Study of a Combination Product Containing Sumatriptan Succinate and Naproxen Sodium for the Treatment of Migraine in Adolescents Study Listed on ClinicalStudyDataRequest.com
USA30226 Completed A randomised, open-label, multicentre, parallel group study comparing the safety and efficacy of an Ultiva (remifentanil hydrochloride) based analgesia/sedation regimen with a conventional sedative-based regimen in long-term ICU subjects requiring analgesia and sedation for up to 10 days. Study Listed on ClinicalStudyDataRequest.com
VEG10003 Completed A Phase I, Open-Label, Multiple Dose, Dose Escalation Study of GW786034 in Patients with Solid Tumors
VEG10004 Completed An Open-Label, Two-Part Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of Pazopanib (GW786034) and the Absorption, Distribution, Metabolism and Elimination of a Single Oral [14C] Labeled Dose of Pazopanib in Subjects with Solid Tumor Malignancies
VEG10005 Completed An Open-Label, Two-Period, Randomized, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of Single Doses of Pazopanib in Cancer Patients
VEG10006 Completed An Open-Label, Safety, Pharmacokinetic and Pharmacodynamic Study of Multiple Doses of GW786034 and Lapatinib Concomitantly Administered in Cancer Patients.
VEG10007 Completed A Multi-center, Open-Label, Multiple-probe Drug Interaction Study to Determine the Effects of GW786034 on the Metabolism of Cytochrome P450 Probe Drugs in Patients with Solid Tumors
VEG102616 Completed A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
VEG102857 Completed Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.